MOTION: A randomized, phase 3, placebo-controlled, double-blind study of vimseltinib (DCC-3014) for the treatment of tenosynovial giant cell tumor.

Journal of Clinical Oncology, vol. 40, pp. TPS11590

Abstract

TPS11590 Background: Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive neoplasm that occurs in the synovium of joints, bursae, or tendon sheaths. TGCT is caused by upregulation of the colony-stimulating factor 1 (CSF1) gene, resulting in aberrant CSF1 expression and the recruitment of CSF1 receptor (R)-dependent inflammatory cells. Resection is the primary treatment, but nonsurgical treatment options are necessary for patients with symptomatic TGCT not amenable to surgical resection. Vimseltinib is an oral switch control TKI specifically designed to selectively and potently inhibit CSF1R. In a Phase 1/2 study in patients with TGCT, vimseltinib showed encouraging antitumor activity with an overall objective response rate (ORR) of 42% in the cohort receiving 30 mg twice weekly (recommended phase 2 dose; Gelderblom et al, ESMO 2021 Poster). Vimseltinib was also well tolerated, and the majority of the common (≥15%) treatment-emergent adverse events (TEAEs) were Grades 1–2. Among these common TEAEs, the only Grade 3–4 event in the Phase 2, twice-weekly, 30-mg cohort was increased blood creatine phosphokinase (CPK); however, this elevated CPK was not associated with any symptoms (Gelderblom et al, ESMO 2021 Poster). Phase 1/2 efficacy and safety data support further development of vimseltinib; here, we describe the ongoing Phase 3 study for patients with TGCT not amenable to surgical resection. Methods: MOTION (NCT05059262) is a Phase 3, randomized, placebo-controlled, double-blind study that aims to evaluate the efficacy and safety of vimseltinib for the treatment of TGCT not amenable to surgical resection. Participants must be at least 18 years of age and have histologically confirmed and symptomatic TGCT for which surgical resection will potentially cause worsening functional limitation or severe morbidity. Prior CSF1R therapy is not permitted (previous imatinib and nilotinib is allowed). In Part 1 of the study, eligible participants will be randomized 2:1 to receive either vimseltinib 30 mg twice a week or matched placebo for 24 weeks. The primary outcome measure is ORR assessed by central read using Response Evaluation Criteria in Solid Tumors version 1.1 at 25 weeks. Secondary outcome measures include ORR per tumor volume score, range of motion, and patient-reported outcomes. Participants assigned to placebo in Part 1 will have the option to receive vimseltinib in Part 2, a long-term treatment phase in which participants will receive open-label vimseltinib. This international study plans to randomize 120 participants and is currently enrolling. Clinical trial information: NCT05059262.

Authors 10

1. William D. Tap

   Memorial Sloan Kettering Cancer Center

   Affiliation as printed

   Memorial Sloan Kettering Cancer Center, New York, NY;

2. Andrew J. Wagner

   Dana-Farber Cancer Institute

   Affiliation as printed

   Center for Sarcoma and Bone Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;

3. Maitreyi G. Sharma

   Deciphera Pharmaceuticals (United States)

   Affiliation as printed

   Deciphera Pharmaceuticals, Waltham, MA;

4. Marc Vallee

   Deciphera Pharmaceuticals (United States)

   Affiliation as printed

   Deciphera Pharmaceuticals, Waltham, MA;

5. Mary F. Michenzie

   Deciphera Pharmaceuticals (United States)

   Affiliation as printed

   Deciphera Pharmaceuticals, Waltham, MA;

6. Matthew Leigh Sherman

   Deciphera Pharmaceuticals (United States)

   Affiliation as printed

   Deciphera Pharmaceuticals, Waltham, MA;

7. Rodrigo Ruiz‐Soto

   Deciphera Pharmaceuticals (United States)

   Affiliation as printed

   Deciphera Pharmaceuticals, Waltham, MA;

8. Silvia Stacchiotti

   Fondazione IRCCS Istituto Nazionale dei Tumori

   Affiliation as printed

   Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;

9. Michiel A. J. van de Sande Aachen

   Leiden University Medical Center

   Affiliation as printed

   Leiden University Medical Center, Leiden, Netherlands;

10. Hans A. J. Gelderblom Aachen

    Leiden University Medical Center

    Affiliation as printed

    Leiden University Medical Center, Leiden, Netherlands;